CY1012A - Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby - Google Patents

Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby

Info

Publication number
CY1012A
CY1012A CY1012A CY101273A CY1012A CY 1012 A CY1012 A CY 1012A CY 1012 A CY1012 A CY 1012A CY 101273 A CY101273 A CY 101273A CY 1012 A CY1012 A CY 1012A
Authority
CY
Cyprus
Prior art keywords
components
obtainned
acetals
steroid
separation
Prior art date
Application number
CY1012A
Other languages
English (en)
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of CY1012A publication Critical patent/CY1012A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CY1012A 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby CY1012A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (fi) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
CY1012A true CY1012A (en) 1979-11-23

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1012A CY1012A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby

Country Status (17)

Country Link
US (1) US3928326A (fi)
JP (1) JPS547794B2 (fi)
BE (1) BE799728A (fi)
CA (1) CA1003402A (fi)
CY (1) CY1012A (fi)
DE (1) DE2323216C3 (fi)
DK (1) DK133249C (fi)
FI (1) FI50711C (fi)
FR (1) FR2185406B1 (fi)
GB (1) GB1428416A (fi)
HK (1) HK49079A (fi)
IL (1) IL42154A (fi)
KE (1) KE2969A (fi)
NL (1) NL175917C (fi)
SE (1) SE378110B (fi)
SU (1) SU468408A3 (fi)
ZA (1) ZA732956B (fi)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
CZ171095A3 (en) * 1993-01-08 1996-01-17 Astra Ab Novel steroidal derivatives specific for colon or ilium
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプｉｖ阻害剤の組成物
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
AP2453A (en) 2007-03-14 2012-08-31 Ranbaxy Lab Ltd Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2993178A1 (en) * 2009-09-11 2016-03-09 CHIESI FARMACEUTICI S.p.A. Glucocorticoid condensed in position 16,17 with an isoxazolidine group
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2698197C2 (ru) 2012-08-24 2019-08-23 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Гетероциклические модуляторы активности hif для лечения заболеваний
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
BR112015006990A2 (pt) 2012-09-28 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de pelo menos um composto
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3538539A2 (en) 2016-11-08 2019-09-18 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MX2022007535A (es) 2019-12-17 2022-09-23 Merck Sharp & Dohme Llc Inhibidores de prmt5.
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
DE2323216A1 (de) 1973-11-29
JPS547794B2 (fi) 1979-04-10
JPS4941379A (fi) 1974-04-18
SU468408A3 (ru) 1975-04-25
NL7306979A (fi) 1973-11-21
FI50711C (fi) 1976-06-10
FR2185406A1 (fi) 1974-01-04
CA1003402A (en) 1977-01-11
GB1428416A (en) 1976-03-17
NL175917C (nl) 1985-01-16
BE799728A (fr) 1973-09-17
FI50711B (fi) 1976-03-01
KE2969A (en) 1979-07-20
DE2323216B2 (de) 1977-11-03
ZA732956B (en) 1974-04-24
DE2323216C3 (de) 1978-06-22
NL175917B (nl) 1984-08-16
SE378110B (fi) 1975-08-18
US3928326A (en) 1975-12-23
IL42154A0 (en) 1973-07-30
DK133249C (da) 1976-09-13
HK49079A (en) 1979-07-27
DK133249B (da) 1976-04-12
AU5525273A (en) 1974-11-07
FR2185406B1 (fi) 1976-12-31
IL42154A (en) 1976-12-31

Similar Documents

Publication Publication Date Title
CY1012A (en) Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby
ZA734896B (en) Novel steroids of the androstane series
YU129173A (en) Process for obtaining steroids
ZA73539B (en) Method for separating monosaccharides from mixtures including di-,and higher saccharides
ZA717190B (en) Process for the preparation of phenol-resin foam materials
ZA734050B (en) Enol derivatives and process for their manufacture
KR780000673B1 (en) Method of manufacturing steroids of the pregnane series
ZA726559B (en) Process for the preparation of steroids of the prednisolone series
AU478324B2 (en) A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
YU34700B (en) Process for obtaining steroids of the pregnane series
CA890949A (en) Separating mixtures of stereoisomeric diaminodicyclohexylalkane
IL35791A (en) Process for the preparation of steroids
IE38097B1 (en) Process for the preparation of n-hexakis-(hydroxymethyl)-melamine and ethers derived therefrom
CA784218A (en) Process for the separation of mixtures of substances
CA910299A (en) Process for the preparation of steroids
CA902039A (en) Process for the preparation of steroids
CA895492A (en) Process and device for the separation of molecules of different masses
CA709851A (en) 16-fluoro compounds of the pregnane series and process for the preparation thereof
CA892477A (en) Process of beneficiation
AU437440B2 (en) Method for separation of oxygen-nitrogen mixtures
AU404940B2 (en) Process for the preparation of 17a-ethynyl-19-nor steroids
CA723705A (en) Process for the preparation of polycaprolactam foams
AU3923668A (en) Method of obtaining shaped masses of porous material
AU5872765A (en) Process for the preparation of 17a-ethynyl-19-nor steroids
ZM16573A1 (en) Process for the separation of nickel values